Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

@article{Ophorst2006ImmunogenicityAP,
  title={Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.},
  author={Olga J. A. E. Ophorst and Katarina Rado{\vs}evi{\'c} and Menzo J. E. Havenga and Maria Grazia Pau and Lennart Holterman and Ben Berkhout and Jaap Goudsmit and Moriya Tsuji},
  journal={Infection and immunity},
  year={2006},
  volume={74 1},
  pages={313-20}
}
Given the promise of recombinant adenovirus type 5 (rAd5) as a malaria vaccine carrier in preclinical models, we evaluated the potency of rAd35 coding for Plasmodium yoelii circumsporozoite protein (rAd35PyCS). We chose rAd35 since a survey with serum samples from African subjects demonstrated that human Ad35 has a much lower seroprevalence of 20% and a much lower geometric mean neutralizing antibody titer (GMT) of 48 compared to Ad5 (seroprevalence, 85%; GMT, 1,261) in countries with a high… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…